Shalby Limited runs a chain of multi-specialty hospitals in India, with a focus on orthopedics and oncology, and also manufactures medical implants under Shalby MedTech. In Q3 FY26 (quarter ended December 2025), the standalone hospital business posted revenue of INR221 crores, down 2.6% year on year, while MedTech consolidated revenue grew 29% to INR303.8 million. Hospital occupancy stood at 44% (47% excluding Shalby International), and the company claims the global number one position in arthroplasty volumes. The hospital EBITDA margin was 16% in Q3 FY26, down from 21.5% a year earlier, while MedTech turned EBITDA positive for the first time, at INR0.7 million, versus a loss of INR69 million in Q3 FY25. These numbers reveal a business that has seen its core hospital margins compress but is now leveraging its own implant supply chain to improve profitability.
The persistence of economics hinges on the implant business's regulatory and qualification cycle. MedTech has received approvals in Malaysia and Argentina, submitted dossiers in South Korea, Vietnam, and Iran, and is in active discussions in five other countries. Within its own hospitals, over 70-80% of implants used in January 2026 are now Shalby's own products, up from 15-20% in Q3 FY26 (which ended December 2025). This vertical integration reduces cost of goods to about 50% of what they were 4.5 years ago, and creates switching costs for surgeons once they are trained on Shalby's systems. However, the hospital business itself faces intense competition from new hospitals in Indian cities, which are willing to "pay any price" for market share, as management noted. The company's existing infrastructure can support 60-70% more work without significant capital expenditure, but that capacity only becomes valuable if occupancy rises.
The near-term triggers include the commissioning of two new linear accelerator bunkers in Ahmedabad and Surat, expected to start contributing in March 2026, and two more in Mohali and Delhi NCR over the next 12-18 months. Shalby International (Gurugram) is targeting an average of 40 occupied beds per day for FY27, up from about 20 now, and expects to become EBITDA positive after a two-quarter delay. Management has guided to double-digit volume growth and 5-6% ARPOB growth in the hospital business for FY27. On the MedTech side, the company is targeting INR600-650 crores of revenue by 2030, with double-digit EBITDA margins above 15%, and is transitioning from turnaround to structured growth. Eighteen to twenty-four months from now, by around mid-2028, the hospital business could be running at an occupancy of 50-55% on the existing bed base, with revenue growing 15% annually, and MedTech contributing meaningfully to consolidated EBITDA as it scales across new geographies. The move to a 25% tax rate for Shalby Limited would also add a recurring profitability boost.
Management's track record is mixed. On the Q1 FY26 call in August 2025, they guided to 12-15% consolidated revenue growth for FY26, but nine-month revenue is flat year over year, and Q3 FY26 revenue declined 0.6%. They projected occupancy to rise from 45% to 50%+ in FY26; instead, Q3 occupancy was 44%. EBITDA margin guidance for improvement through the year has not materialised, as consolidated margin fell from 14% to 13.4% year on year. However, they have delivered on the transplant business: MedTech turned EBITDA positive in Q3, the $100 million revenue aspiration for MedTech is reiterated, and new product launches and regulatory progress are on track. Capex timelines for the Mumbai hospital and Sanar breakeven have slipped by 1-2 quarters. The company has also invested over INR80 crores in robotics and diagnostics in the last 8-9 months, yet plans no significant hospital capex in the next 12 months. Net debt stands at INR408 crores (gearing 0.41x), and management expects it to be lower in a year as MedTech reduces its funding needs.
The quantified earnings path for FY27 implies hospital revenue growth of at least 15% (double-digit volume plus 5-6% ARPOB), which would lift standalone hospital EBITDA from the current 16% margin toward the normalized 20% level as fixed costs are absorbed. MedTech's EBITDA is already positive, and with cost optimisation, gross margin expansion, and new product launches, the segment should move closer to PAT breakeven. The single most important watchpoint is hospital occupancy: if it remains stuck in the mid-40s, the operating leverage story fails. Additionally, the insurance contract renegotiation that caused a 2-2.5 month pause in Q3 must not recur. The tax benefit from the 25% rate is another factor; if MAT issues delay it, the earnings uplift will be postponed. Resolving the tension between management's missed financial guidance and delivered operational milestones requires patience: the underlying capacity and competitive position are intact, but execution risk remains elevated. If occupancy and volume growth materialise, the business in 18-24 months will have higher revenue, better margins, and a profitable MedTech arm, making it an operating-leverage story.
companyname: Shalby Limited ticker: SHALBY sector: Healthcare - Multi-speciality Hospitals & Orthopaedic Implants Shalby Limited is a healthcare conglomerate that operates two distinct but interconnected businesses: a network of multi-speciality hospitals and a global orthopaedic implant manufacturing and distribution business. The company was founded in 1994 as a six-bed orthopaedic hospital in Ahmedabad and has grown into Western India's largest corporate hospital network, with 15 hospitals (...
Read the full report →capex, margin expansion
No guidance
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Shalby Limited and 4,900+ companies.
5-day free pass. No card required.